All In Biotech

NDA 021789 · Galderma Labs Lp

Metrogel

Metronidazole · Topical · Nitroimidazole Antimicrobial

Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Jun 30, 2005

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

132 Phase 3, 52 recruiting

FAERS reports

48,091

41,901 serious, 5,412 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 31, 2024.

Metronidazole Gel, 1% is indicated for the topical treatment of inflammatory lesions of rosacea. Metronidazole Gel, 1% is a nitroimidazole indicated for the topical treatment of inflammatory lesions of rosacea. ( 1 )

Mechanism: The mechanism of action of metronidazole in the treatment of rosacea is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • METROGEL · METRONIDAZOLE 1% · GEL, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Metronidazole" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,655
  • nausea3,458
  • off label use3,383
  • diarrhoea2,713
  • vomiting2,329
  • pyrexia2,288
  • headache2,258
  • abdominal pain2,119
  • pain2,119
  • fatigue1,959
  • dizziness1,684
  • condition aggravated1,634

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004459
2005480
2006482
2007511
2008320
2009676
2010858
20111,164
20121,431
20131,112
20141,451
20152,167
20162,469
20172,507
20184,185
20194,489
20203,817
20213,868
20223,400
20233,458
20243,160
20253,437
20262,187

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Metrogel (Metronidazole)

2024 spending

$40K

Beneficiaries

60

83 claims

Per beneficiary

$671

$5.94 per unit

View as table
YearSpending
2020$257,442
2021$218,923
2022$194,436
2023$150,789
2024$40,245

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3,032 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.